<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Drug Investig</journal-id><journal-id journal-id-type="iso-abbrev">Clin Drug Investig</journal-id><journal-title-group><journal-title>Clinical Drug Investigation</journal-title></journal-title-group><issn pub-type="ppub">1173-2563</issn><issn pub-type="epub">1179-1918</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23975657</article-id><article-id pub-id-type="pmc">3775191</article-id><article-id pub-id-type="publisher-id">91</article-id><article-id pub-id-type="doi">10.1007/s40261-013-0091-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Effective Achievement of Hemoglobin Stability with Once-Monthly C.E.R.A. in Peritoneal Dialysis Patients: A Prospective Study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Koch</surname><given-names>Michael</given-names></name><address><phone>+49-2104-979960</phone><fax>+49-2104-9799624</fax><email>koch@dialyse-mettmann.de</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Treiber</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Fliser</surname><given-names>Danilo</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><aff id="Aff1"><label/>Nephrology Center, Gartenstrasse 8, 40822 Mettmann, Germany </aff><aff id="Aff2"><label/>Renal and Hypertension Center Mittelrhein, 56456 Neuwied, Germany </aff><aff id="Aff3"><label/>Department of Internal Medicine IV, Saarland University, Medical Centre, 66421 Homburg/Saar, Germany </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>8</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>8</month><year>2013</year></pub-date><pub-date pub-type="ppub"><year>2013</year></pub-date><volume>33</volume><issue>10</issue><fpage>699</fpage><lpage>706</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2013</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Correction of low hemoglobin (Hb) levels is associated with improved survival and greater quality of life in dialysis patients, but frequent administration of erythropoiesis stimulating agent (ESA) therapy is unsatisfactory for peritoneal dialysis patients.</p></sec><sec><title>Objective</title><p>The objective of this study was to assess Hb stability in an unselected population of maintenance peritoneal dialysis patients receiving once-monthly treatment with C.E.R.A., a continuous erythropoietin receptor activator.</p></sec><sec><title>Methods</title><p>In a prospective, non-interventional, single-arm study at 33 Germany dialysis centers, peritoneal dialysis patients with or without ESA treatment prior to study entry received once-monthly treatment with C.E.R.A. Hb stability was assessed by the proportion of patients for whom all measured Hb values during months 6&#x02013;8 (the evaluation phase) were within the range 11&#x02013;12, 11&#x02013;13, 10&#x02013;12 or 11&#x02013;12.5&#x000a0;g/dL.</p></sec><sec><title>Results</title><p>220 patients received at least one dose of C.E.R.A. During the evaluation phase, 185 patients provided &#x02265;1 Hb measurement (efficacy population) and 162 patients provided &#x02265;2 Hb measurements (the modified efficacy population). The mean (SD) time between C.E.R.A. doses was 28.2 (7.2) days and mean (SD) C.E.R.A. dose was 109 (57)&#x000a0;&#x003bc;g per application. Mean (SD) Hb level was 11.1 (1.4)&#x000a0;g/dL at baseline and 11.5 (1.3)&#x000a0;g/dL at the end of the study (modified efficacy population). The primary efficacy variable, all measured Hb values in the range 11&#x02013;12&#x000a0;g/dL, was 18.4&#x000a0;% (34/185) and 14.8&#x000a0;% (24/162) in the efficacy and modified efficacy populations, respectively. The mean (SD) maximum intra-individual fluctuation in Hb level was 0.56 (0.50)&#x000a0;g/dL in the efficacy population and 0.58 (0.49)&#x000a0;g/dL in the modified efficacy population, with maximum intra-individual fluctuation &#x02264;1&#x000a0;g/dL in 85.4&#x000a0;% (158/185) and 83.3&#x000a0;% (135/162) of patients, respectively. No adverse drug reactions were reported during the study.</p></sec><sec><title>Conclusion</title><p>In this large population of maintenance peritoneal dialysis patients, once-monthly administration of C.E.R.A. achieved a high degree of Hb stability and was well-tolerated.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing Switzerland 2013</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="intro"><title>Introduction</title><p>Anemia is a well-recognized complication of end-stage renal disease, arising from inadequate production of erythropoietin by the failing kidney in response to declining hemoglobin (Hb) concentration. By the time dialysis is required, approximately three-quarters of patients are anemic [<xref ref-type="bibr" rid="CR1">1</xref>]. In addition to the classic symptom of fatigue [<xref ref-type="bibr" rid="CR2">2</xref>], the presence of anemia in patients with peritoneal dialysis contributes to increased cardiovascular risk [<xref ref-type="bibr" rid="CR3">3</xref>], increased insulin resistance [<xref ref-type="bibr" rid="CR4">4</xref>] and risk of mortality [<xref ref-type="bibr" rid="CR5">5</xref>]. An analysis of data from almost 14,000 peritoneally dialyzed patients demonstrated that Hb levels below 11.0&#x000a0;g/dL, and particularly levels less than 10&#x000a0;g/dL, were associated with a higher risk of both hospitalization and mortality [<xref ref-type="bibr" rid="CR5">5</xref>]. Observational evidence that correction of low Hb levels is associated with improved survival in dialysis patients [<xref ref-type="bibr" rid="CR6">6</xref>], as well as greater quality of life [<xref ref-type="bibr" rid="CR7">7</xref>], has led to recommendations that a Hb level of 11&#x02013;12&#x000a0;g/dL should be targeted in dialysis patients receiving erythropoiesis stimulating agent (ESA) therapy, with the aim of not exceeding 13&#x000a0;g/dL [<xref ref-type="bibr" rid="CR8">8</xref>]. More recently, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines have proposed that ESA maintenance therapy not be used to maintain Hb levels above 11.5&#x000a0;g/dL in adult patients with CKD, and recommend that ESAs not be used to intentionally increase Hb above 13.0&#x000a0;g/dL [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>Since the introduction of recombinant human erythropoietin preparations in 1989, the previously widespread problem of severe anemia in end-stage renal disease had been largely overcome. However, such therapies have a relatively short half-life, requiring administration as often as twice or three times a week. For the peritoneal dialysis patient this necessitates regular clinical visits or frequent self-injection at home, which is both unsatisfactory and can affect compliance. Darbepoetin alfa, which has a somewhat longer half-life than epoetin alfa or beta (~25&#x000a0;h [<xref ref-type="bibr" rid="CR10">10</xref>] compared to &#x02264;9&#x000a0;h [<xref ref-type="bibr" rid="CR11">11</xref>]) and is routinely used once a week, has been assessed for once-monthly dosing in peritoneal dialysis patients in small non-comparative series, but was not always adequate to maintain Hb levels [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>].</p><p>The pharmacokinetic characteristics of the continuous erythropoietin receptor activator C.E.R.A., including a long half-life (~130&#x000a0;h), a relatively low binding affinity for the erythropoiesis receptor and low systemic clearance [<xref ref-type="bibr" rid="CR15">15</xref>], permit once-monthly dosing. The efficacy of once-monthly C.E.R.A. in hemodialysis patients is similar to shorter-acting ESA agents in terms of maintaining Hb levels [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. Clinical experience in hemodialysis patients suggests that conversion from more frequently administered ESA therapies to once-monthly C.E.R.A. is convenient and maintains good control of Hb levels [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Results from the hemodialysis setting, however, are not necessarily applicable to peritoneal dialysis patients. Anemia control with ESA therapy appears to be more readily achieved in peritoneal dialysis patients than in patients receiving hemodialysis [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. A large analysis of US Medicare data from 1995&#x02013;2000 showed that although ESA therapy was much less frequent in peritoneal dialysis patients (25 versus 80&#x000a0;% of hemodialysis patients), with 50&#x000a0;% lower doses, Hb levels were similar between the two groups [<xref ref-type="bibr" rid="CR23">23</xref>]. Similarly, a multicenter comparative study in France observed that mean Hb levels were similar in the peritoneal dialysis or hemodialysis subpopulations but that this was achieved in the peritoneally dialyzed patients with a significantly lower dose of ESA at a lower frequency of administration, and with a reduced rate of intravenous iron therapy [<xref ref-type="bibr" rid="CR24">24</xref>]. In routine practice, both ESA dose [<xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>] and use of intravenous iron [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR27">27</xref>] is often lower in peritoneal dialysis patients compared to the hemodialysis population. Several factors may be involved in the difference in anemia control between dialysis modalities. Better depuration of erythropoiesis inhibitors during peritoneal dialysis, superior preservation of residual renal function, absence of blood loss from hemodialysis sessions, and greater adequacy of dialysis in terms of frequency and duration may all play a role [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>] although their relative contributions are difficult to determine.</p><p>The present study was a prospective, multicenter, observational trial undertaken to assess Hb stability in an unselected population of maintenance peritoneal dialysis patients receiving C.E.R.A. therapy once a month.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Study Design and Conduct</title><p>This was a prospective, non-interventional, single-arm study conducted at 33 nephrology centers in Germany during the period April 2009 to March 2011. Following enrolment, all patients received C.E.R.A. therapy once a month. The dose of C.E.R.A. was titrated during the first six months post-baseline (the titration phase), with an evaluation phase during the following three months (months 6&#x02013;8).</p><p>The study was undertaken in accordance with German Medicines Act, as a non-interventional study. The observational plan and the informed consent form were approved by the local ethics committee for the lead investigator (MK) (&#x000c4;rztekammer Nordrhein, D&#x000fc;sseldorf). All study participants provided written informed consent. Roche Pharma AG (Germany) funded the study, including data analysis by a contract research association, and reviewed the manuscript. All data collection was undertaken by the study investigators.</p></sec><sec id="Sec4"><title>Patient Population</title><p>Patients were eligible for inclusion if they were receiving peritoneal dialysis and, in the opinion of the investigator, required ESA therapy. Patients were required to have a life expectancy of more than 9&#x000a0;months and to have iron indices within the limits defined by the European Best Practice Guidelines (serum ferritin &#x02265;100&#x000a0;ng/mL and transferrin saturation (TSAT) &#x02265;20&#x000a0;%) [<xref ref-type="bibr" rid="CR30">30</xref>]. Exclusion criteria comprised active malignancy, acute infection, acute bleeding, decrease in Hb level within the 4&#x000a0;weeks prior to inclusion (as defined by the investigator), and pregnancy. Patients could be receiving ESA therapy at the time of study entry. Patients were to be withdrawn from the study if an ESA agent other than C.E.R.A. was initiated or if hemodialysis was started.</p></sec><sec id="Sec5"><title>Medication</title><p>Prior to study entry, any ESA therapy was administered by the physician according to local practice and the summary of product characteristics of the selected ESA. All patients received C.E.R.A therapy from study entry, prescribed according to local practice. Dose changes were made at the discretion of the investigator.</p></sec><sec id="Sec6"><title>Data Collection</title><p>Study visits took place at study entry and then monthly up to nine months after the baseline visit. Assessments took place at routine clinical visits. If a patient discontinued C.E.R.A. prematurely or started hemodialysis, a final assessment was carried out but no further data were documented.</p><p>At study entry, the following data were collected: demographics, concomitant disease, cause of end-stage renal disease, duration of peritoneal dialysis, type of previous ESA therapy during the preceding 16&#x000a0;weeks if relevant, use of C.E.R.A. during the preceding 16&#x000a0;weeks, reason for switch to C.E.R.A., current Hb level prior to C.E.R.A. dose at study entry and laboratory values [iron status, hematology, liver function, estimated glomerular filtration rate (eGFR) calculated by the Modification in Renal Disease (MDRD) formula [<xref ref-type="bibr" rid="CR31">31</xref>], C-reactive protein, vitamin B12, renal and peritoneal <italic>Kt</italic>/<italic>V</italic> (where <italic>K</italic> is dialyzer clearance of urea, <italic>t</italic> is dialysis time and <italic>V</italic> is the volume of distribution of urea), parathyroid hormone and albumin]. At all post-baseline study visits, the following data were recorded: Hb level prior to C.E.R.A. administration, laboratory values and changes in concomitant disease/medication. Adverse drug reactions were to be documented, including duration, severity, whether the event was regarded as serious, and causal relationship with C.E.R.A.</p><p>Data were recorded by study investigators on printed forms or electronically. Printed data entries were sent directly to an independent clinical research organization (M.A.R.C.O GmbH &#x00026; Co KG, 40227 D&#x000fc;sseldorf, Germany), where data were entered to the study database. Electronic data capture contained the same information as the printed forms. The clinical research organization was responsible for clarifying discrepancies on the submitted forms and obtaining additional information from physicians as necessary.</p></sec><sec id="Sec7"><title>Statistical Analysis</title><p>All data are presented descriptively with no formal statistical analyses, as planned in the study protocol. Stability of Hb was assessed by the proportion of patients for whom all measured Hb values during months 6&#x02013;8 (the evaluation phase) were within the range 11&#x02013;12, 11&#x02013;13, 10&#x02013;12 or 11&#x02013;12.5&#x000a0;g/dL. The maximum intra-individual fluctuation in Hb values was defined as the maximum absolute difference from the individual mean Hb value during the evaluation phase.</p><p>The safety population comprised all patients who received at least one dose of C.E.R.A. The efficacy population comprised all patients in the safety population who provided at least one post-baseline measurement of Hb concentration. The modified efficacy population consisted of all patients in the efficacy population for whom at least two Hb measurements were available during the evaluation period. A pre-defined subanalysis was performed based on patients in the efficacy population who did not receive C.E.R.A. prior to the study. For patients in whom C.E.R.A. therapy was stopped before the end of the observation period, data were analyzed to the point of discontinuation.</p><p>All analyses were descriptive. Statistical analyses were performed using SAS<sup>&#x000ae;</sup> Version 9.1.3 (SAS Institute, Cary, NC, USA)</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><sec id="Sec9"><title>Patient Population</title><p>A total of 223 patients were enrolled; 220 (98.7&#x000a0;%) received at least one dose of C.E.R.A. and formed the safety population. Of these, 219 patients (99.5&#x000a0;%) provided at least one post-baseline Hb measurement and were included in the efficacy population: 185 of these patients provided at least one Hb measurement during the evaluation phase. The modified efficacy population comprised 162/219 patients (74.0&#x000a0;%) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The nine-month study was completed by 167/220 patients (75.9&#x000a0;%), with the most frequent reason for discontinuation being switch to hemodialysis (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Patient disposition. <italic>C.E.R.A.</italic> continuous erythropoietin receptor activator, <italic>Hb</italic> hemoglobin, <italic>ESA</italic> erythropoiesis stimulating agent</p></caption><graphic xlink:href="40261_2013_91_Fig1_HTML" id="MO1"/></fig></p><p>The mean age of the population was approximately 57&#x000a0;years and slightly more than half the patients (113/220, 51.4&#x000a0;%) were male (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Concomitant cardiac disorders and diabetes mellitus type 2 were present in 40.9 and 18.1&#x000a0;% of patients, respectively. At time of study entry, the mean duration of peritoneal dialysis was 3.0&#x000a0;years (range 1&#x02013;15&#x000a0;years). Most patients (135/220, 61.4&#x000a0;%) were receiving continuous ambulatory peritoneal dialysis (CAPD).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Patient characteristics at study entry (safety population, <italic>n</italic>&#x000a0;=&#x000a0;220)</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="2">Age (years)</td></tr><tr><td align="left">&#x000a0;Mean (SD)</td><td align="left">56.9 (15.1)</td></tr><tr><td align="left">&#x000a0;Median (range)</td><td align="left">61 (19&#x02013;93)</td></tr><tr><td align="left">Male [<italic>n</italic> (%)]</td><td align="left">113 (51.4)</td></tr><tr><td align="left" colspan="2">Body mass index (kg/m<sup>2</sup>)</td></tr><tr><td align="left">&#x000a0;Mean (SD)</td><td align="left">26.0 (4.6)</td></tr><tr><td align="left">&#x000a0;Median (range)</td><td align="left">25.5 (13.7&#x02013;48.5)</td></tr><tr><td align="left">Caucasian [<italic>n</italic> (%)]</td><td align="left">215 (96.4)</td></tr><tr><td align="left" colspan="2">Concomitant conditions [<italic>n</italic> (%)]</td></tr><tr><td align="left">&#x000a0;Cardiac disorders</td><td align="left">90 (40.9)</td></tr><tr><td align="left">&#x000a0;Diabetes mellitus (type 2)</td><td align="left">40 (18.2)</td></tr><tr><td align="left" colspan="2">Duration of peritoneal dialysis (years)</td></tr><tr><td align="left">&#x000a0;Mean (SD)</td><td align="left">3.0 (2.1)</td></tr><tr><td align="left">&#x000a0;Median (range)</td><td align="left">2.0 (1&#x02013;15)</td></tr><tr><td align="left" colspan="2">Type of peritoneal dialysis [<italic>n</italic> (%)]</td></tr><tr><td align="left">&#x000a0;Continuous ambulatory</td><td align="left">135 (61.4)</td></tr><tr><td align="left">&#x000a0;Ambulatory</td><td align="left">65 (29.5)</td></tr><tr><td align="left">&#x000a0;Intermittent</td><td align="left">19 (8.6)</td></tr><tr><td align="left" colspan="2">eGFR (mL/min/1.73&#x000a0;m<sup>2</sup>)</td></tr><tr><td align="left">&#x000a0;Mean (SD)</td><td align="left">9.9 (12.5)</td></tr><tr><td align="left">&#x000a0;Median (range)</td><td align="left">7.0 (1.2&#x02013;76.5)</td></tr><tr><td align="left" colspan="2">C-reactive protein (mg/L)</td></tr><tr><td align="left">&#x000a0;Mean (SD)</td><td align="left">7.2 (9.0)</td></tr><tr><td align="left">&#x000a0;Median (range)</td><td align="left">5.2 (0.5&#x02013;40.0)</td></tr><tr><td align="left" colspan="2">Hb (g/dL)</td></tr><tr><td align="left">&#x000a0;Mean (SD)</td><td align="left">11.1 (1.3)</td></tr><tr><td align="left">&#x000a0;Median (range)</td><td align="left">11.1 (5.4&#x02013;15.7)</td></tr></tbody></table><table-wrap-foot><p>
<italic>eGFR</italic> estimated glomerular filtration rate, <italic>Hb</italic> hemoglobin, <italic>SD</italic> standard deviation</p></table-wrap-foot></table-wrap></p><p>Mean (SD) Hb at baseline was 11.1 (1.3)&#x000a0;g/dL, with a median value of 11.1 (range 5.4&#x02013;15.7&#x000a0;g/dL) in the safety population. Sixty patients (27.3&#x000a0;%) were receiving oral iron supplementation and 40 patients (18.2&#x000a0;%) were receiving intravenous iron; a further four patients (0.2&#x000a0;%) were receiving unspecified iron preparations. The last post-baseline values for median serum ferritin and TSAT were 114&#x000a0;ng/mL (<italic>n</italic>&#x000a0;=&#x000a0;160) and 26.9&#x000a0;% (<italic>n</italic>&#x000a0;=&#x000a0;146), respectively.</p><p>In the 16&#x000a0;weeks prior to study entry, 75.9&#x000a0;% of patients in the safety population (167/220) had received ESA therapy. Of the 106 patients who received previous non-C.E.R.A. ESA therapy, this comprised darbepoetin alfa [<italic>n</italic>&#x000a0;=&#x000a0;72 (32.7&#x000a0;%)], epoetin beta [<italic>n</italic>&#x000a0;=&#x000a0;24 (10.9&#x000a0;%)], epoetin zeta [<italic>n</italic>&#x000a0;=&#x000a0;15 (6.8&#x000a0;%)] and epoetin alfa [<italic>n</italic>&#x000a0;=&#x000a0;11 (5.0%)] (more than one ESA therapy was possible). In total, 61 patients in the safety population received C.E.R.A. prior to study entry. In the modified efficacy population, 47 patients had previously received C.E.R.A.</p></sec><sec id="Sec10"><title>C.E.R.A Administration</title><p>The mean (SD) dose of C.E.R.A. per application was 109 (57)&#x000a0;&#x003bc;g throughout the study, equivalent to 3.5 (2.1) &#x003bc;g/day [total cumulative dose 1,040 (625)&#x000a0;&#x003bc;g]. The most frequent initial doses were 50&#x000a0;&#x003bc;g (38/220, 17.3&#x000a0;%), 75&#x000a0;&#x003bc;g (48/220, 21.8&#x000a0;%) and 100&#x000a0;&#x003bc;g (43/220, 19.5&#x000a0;%). The mean dose of C.E.R.A. per application remained stable from baseline [110 (63)&#x000a0;&#x003bc;g] to month 9 [103 (61)&#x000a0;&#x003bc;g]. During the nine-month study period, 138 patients (62.7&#x000a0;%) required one or more C.E.R.A. dose change, while the remaining 82 patients (37.3&#x000a0;%) remained on their initial dose. The proportions of patients receiving a dose increase (106/220, 48.2&#x000a0;%) or a dose decrease (111/220, 50.5&#x000a0;%) were similar, with a mean of 0.9 dose increases and 0.8 dose decreases per patient during the study. In total, the mean (SD) number of dose changes per patient during the study was 1.7 (1.8).</p><p>Of the 2,097 C.E.R.A. doses administered during the study, 1,972 (94.0&#x000a0;%) were given subcutaneously and 92 (4.4&#x000a0;%) intravenously (route was unknown for 33 doses). Doses were administered in the clinic (85/220 patients, 38.6&#x000a0;%), at home (78/220, 35.5&#x000a0;%) or both (57/220, 25.9&#x000a0;%).</p><p>The mean (SD) time between C.E.R.A. doses was 28.2 (7.2)&#x000a0;days.</p></sec><sec id="Sec11"><title>Efficacy</title><p>Mean (SD) Hb level was 11.1 (1.4)&#x000a0;g/dL at baseline and 11.5 (1.3)&#x000a0;g/dL at the end of the study (modified efficacy population) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). A small initial rise after study entry was attributed to the 53 patients who were not previously receiving ESA therapy prior to study, in whom mean (SD) Hb increased from 11.0 (1.4)&#x000a0;g/dL at baseline to 11.5 (1.4)&#x000a0;g/dL one month after initiation of C.E.R.A. therapy and 11.3 (1.5)&#x000a0;g/dL at month 9. For the 106 patients who were receiving non-C.E.R.A. ESA treatment prior to the study, mean (SD) Hb level was 11.3 (1.3)&#x000a0;g/dL at baseline, 11.5 (1.2)&#x000a0;g/dL after one month and 11.7 (1.0)&#x000a0;g/dL at month 9.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Mean (SD) hemoglobin level in all patients, in patients without any erythropoiesis stimulating agent (ESA) therapy prior to study entry, and in patients who received an ESA therapy other than continuous erythropoietin receptor activator (C.E.R.A.) prior to study entry (modified efficacy population, <italic>n</italic>&#x000a0;=&#x000a0;162)</p></caption><graphic xlink:href="40261_2013_91_Fig2_HTML" id="MO2"/></fig></p><p>Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> illustrates the proportion of patients with all available Hb values within pre-specified ranges during the evaluation phase. The proportion of patients in the range 11&#x02013;12&#x000a0;g/dL during the evaluation phase, i.e. the primary efficacy variable, was 18.4&#x000a0;% (34/185) of patients in the efficacy population for whom Hb measurements were provided, and 14.8&#x000a0;% (24/162) in the modified efficacy population. During the evaluation phase, approximately 40&#x000a0;% of patients in the efficacy and the modified efficacy populations had all measured Hb levels within the 10&#x02013;12 or 11&#x02013;13&#x000a0;g/dL ranges (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Among the 115 patients in the modified efficacy population who did not receive C.E.R.A. prior to study entry, 13.9&#x000a0;% (16/115), 38.3&#x000a0;% (44/115) and 38.3&#x000a0;% (44/115) had all Hb values within the ranges 11&#x02013;12, 10&#x02013;12 and 11&#x02013;13&#x000a0;g/dL, respectively. During the evaluation period, approximately 83&#x000a0;% of patients had all Hb values &#x02265;10&#x000a0;g/dL and 87&#x000a0;% of patients had all Hb values &#x02264;13&#x000a0;g/dL in both the efficacy and modified efficacy populations (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Proportion of patients within pre-specified hemoglobin (Hb) ranges during the evaluation phase (months 6&#x02013;8). The efficacy population consisted of patients with at least one Hb value during the evaluation phase (<italic>n</italic>&#x000a0;=&#x000a0;185). The modified efficacy population consisted of all patients in the efficacy population for whom at least two Hb measurements were available during the evaluation period (<italic>n</italic>&#x000a0;=&#x000a0;162)</p></caption><graphic xlink:href="40261_2013_91_Fig3_HTML" id="MO3"/></fig></p><p>The mean (SD) maximum intra-individual fluctuation in Hb level during the evaluation period was 0.56 (0.50)&#x000a0;g/dL in the efficacy population and 0.58 (0.49)&#x000a0;g/dL in the modified efficacy population. The maximum intra-individual fluctuation during the evaluation phase was &#x02264;1&#x000a0;g/dL in 85.4&#x000a0;% (158/185) and 83.3&#x000a0;% (135/162) of patients in the efficacy and modified efficacy populations, respectively.</p></sec><sec id="Sec12"><title>Safety and Tolerability</title><p>No adverse drug reactions were reported during the study. No clinically relevant changes in laboratory values or vital signs were noted during the study.</p></sec></sec><sec id="Sec13" sec-type="discussion"><title>Discussion</title><p>In this large population of maintenance peritoneal dialysis patients, once-monthly administration of C.E.R.A. achieved a high degree of Hb stability and was well-tolerated when administered according to local practice. Conversion from more frequently-administered ESA therapies to C.E.R.A.&#x02014;or introduction of C.E.R.A. as de novo therapy&#x02014;proved convenient, with relatively few doses changes and approximately 65&#x000a0;% of patients administering at least one dose at home.</p><p>Maintaining Hb levels within a narrow target range in dialysis patients is notoriously challenging due to the high degree of Hb variability observed in dialysis populations [<xref ref-type="bibr" rid="CR32">32</xref>]. Indeed, one retrospective study in the Netherlands, which included 56 hemodialysis patients and 12 peritoneal dialysis patients, found that none remained within the target range of 11&#x02013;12&#x000a0;g/dL over a one-year period during ESA therapy [<xref ref-type="bibr" rid="CR33">33</xref>]. The current real-life population is likely to have included more challenging patients than in randomized controlled trials which, for example, frequently specify a baseline Hb range and maximum limits for Hb fluctuation as part of the inclusion criteria. Against this background, the finding that only approximately 15&#x000a0;% of patients in the modified efficacy population achieved the primary variable of all Hb levels within 11&#x02013;12&#x000a0;g/dL during the three-month evaluation phase is not unexpected. Perhaps more relevantly, few patients had Hb values &#x0003c;10&#x000a0;g/dL (approximately 17&#x000a0;%). Importantly, only 13&#x000a0;% had a single Hb value above 13&#x000a0;g/dL during the evaluation period, consistent with recent recommendations from KDIGO [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>The initial doses of C.E.R.A prescribed by the managing physicians were appropriate, as indicated by the largely unchanged mean dose and the similar proportion of dose increases and dose decreases during the study. Multicenter studies in which hemodialysis patients were converted from shorter-acting ESA preparations to monthly C.E.R.A. have reported similar findings [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. It is encouraging that almost 40&#x000a0;% of patients required no dose changes over the 9-month study, with an overall mean of fewer than two dose changes per patient. This is consistent with findings from a pooled analysis of three comparative Phase III trials of C.E.R.A. twice- or once-monthly versus shorter-acting ESAs in hemodialysis patients, in which significantly fewer dose changes were required in the C.E.R.A. treated patients [<xref ref-type="bibr" rid="CR35">35</xref>], and previous observational data in peritoneally dialyzed patients [<xref ref-type="bibr" rid="CR36">36</xref>]. More frequent ESA dose changes show an association with increased Hb fluctuation [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR36">36</xref>], a relationship that appears to be causal [<xref ref-type="bibr" rid="CR36">36</xref>], so a low rate of dose alterations may support stable Hb control. Data from dialysis populations [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>] have suggested that fluctuation from target Hb range to values below 11&#x000a0;g/dL are associated with increased mortality. Here, the mean fluctuation in Hb levels over the nine-month study was ~1.5&#x000a0;g/dL, which compares favorably with published data [<xref ref-type="bibr" rid="CR33">33</xref>]. A retrospective, single-center analysis reported a trend to fewer excursions from Hb target range in C.E.R.A.-treated peritoneal dialysis patients versus those receiving epoetin beta, although complete Hb cycles were similar in both groups [<xref ref-type="bibr" rid="CR36">36</xref>]. The authors concluded that fewer dose changes with C.E.R.A. may offer a small advantage in reducing the degree of Hb variability [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p>Another 9-month observational study with a similar protocol has been conducted in 924 hemodialysis patients [<xref ref-type="bibr" rid="CR20">20</xref>]. Baseline Hb levels were broadly similar to the current population [mean (SD) 11.4 (1.2)&#x000a0;g/dL compared to 11.1 (1.3) g/dL here] [<xref ref-type="bibr" rid="CR20">20</xref>]. During the evaluation phase in the hemodialysis patients, Hb parameters were consistently similar to those seen in the current peritoneal dialysis population, including mean Hb levels, the proportion of patients within pre-specified Hb ranges, the mean intra-individual Hb fluctuation and the proportion of patients with a maximum intra-individual fluctuation &#x02264;1&#x000a0;g/dL. In the hemodialysis patients, however, the mean dose of C.E.R.A. over the nine-month study was 124&#x000a0;&#x003bc;g compared to 109&#x000a0;&#x003bc;g in the current peritoneal dialysis population. Carrera et al. [<xref ref-type="bibr" rid="CR39">39</xref>] described an initial mean C.E.R.A. dose of 159&#x000a0;&#x003bc;g, titrated upwards by protocol to 260&#x000a0;&#x003bc;g. These data are in line with published data showing that higher ESA doses are often required in hemodialysis patients to achieve the same level of Hb control as in peritoneally dialyzed patients [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>].</p><p>With regards the safety profile of C.E.R.A., no adverse drug reaction was reported in this series of over 200 patients during the eight-month period.</p></sec><sec id="Sec14" sec-type="conclusions"><title>Conclusions</title><p>Once-monthly C.E.R.A. was effective and well-tolerated when used in routine clinical practice for the treatment of anemia in peritoneal dialysis patients either following conversion from more frequently-dosed ESA therapies or as de novo treatment. Results in this largely unselected population of peritoneally dialyzed patients suggest that the effectiveness of once-monthly C.E.R.A. in peritoneally dialyzed patients is similar to that observed in hemodialysis patients but that this may be achieved at a slightly lower dose.</p></sec></body><back><app-group><app id="App1"><sec id="Sec15"><title>Appendix: The BEAM Study Investigators</title><p>All locations are in Germany.</p><p>Samih Al-Sarraf, Augsburg; Volker Becker, Heusenstamm; Lucia Bittorf-Rollenhagen, Berlin; Gunnar B&#x000fc;cker, Osnabr&#x000fc;ck; Theo Busch, Moers; Ernst-Gerhard Dannemann, Gelsenkirchen; Tilman David-Walek, Kiel; Ralf Desselberger, Greifswald; Robert Dunst, Reut-lingen; Hans-Herbert Echterhoff, Bielefeld; Danilo Fliser, Homburg; Bj&#x000f6;rn Friedrich, Leonberg; Christian Friedrichsohn, Villingen-Schwennigen; Klaus Fromm-herz, St. Wendel; Georg Georges, T&#x000fc;bingen; Gerd Hetzel, D&#x000fc;ssel-dorf; Martin Kimmel &#x00026; Niko Braun, Stuttgart; R&#x000fc;diger Knaup, Siegen; Michael Koch, Mettmann; Axel Krieter, M&#x000fc;nchen; Heike Martin, Zwickau; Uta Neuh&#x000e4;user-Piduhn, Dortmund; Rainer Nowack, Lindau; Susanne Pawlow-Handt &#x00026; Manfred Schl&#x000f6;cker, Wolfenb&#x000fc;ttel; Sylvia Petersen, Berlin; J&#x000f6;rg Radermacher, Minden; Andreas Raffelsiefer, Warendorf; Thomas Rath, Kai-serslautern; Peter Rawer, Wetzlar; Manfred Schmitt, Speyer; Frank Seibt &#x00026; Erika Eger, Berlin; Wolfgang Treiber &#x00026; Thomas Sures, Neuwied; Sibille Tr&#x000f6;ster, Westerstede; Volker Vielhauer, M&#x000fc;nchen.</p></sec></app></app-group><fn-group><fn><p>On behalf of the BEAM study group. The members of the BEAM study group are listed in <xref rid="Sec15" ref-type="sec">Appendix</xref>.</p></fn></fn-group><ack><p>With grateful thanks to the study investigators (see <xref rid="Sec15" ref-type="sec">Appendix</xref>).</p><sec id="d30e808"><title>Disclosures</title><p><italic>Author contributions</italic>: All authors contributed to the study design, collected clinical data, evaluated the data, critically assessed the manuscript and gave final approval for submission.</p><p><italic>Funding</italic>: The study was supported by Roche Pharma AG, Germany. A freelance medical writer assisted in the development of the manuscript with funding from Roche Pharma AG.</p></sec><sec id="d30e819"><title>Conflict of interest</title><p>MK and WT have no conflicts of interest to declare. DF has received consulting and speaker&#x02019;s honoraria from Amgen, Roche Pharma AG and Ortho Biotech.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClellan</surname><given-names>W</given-names></name><name><surname>Aronoff</surname><given-names>SL</given-names></name><name><surname>Bolton</surname><given-names>WK</given-names></name><etal/></person-group><article-title>The prevalence of anemia in patients with chronic kidney disease</article-title><source>Curr Med Res Opin</source><year>2004</year><volume>20</volume><fpage>1501</fpage><lpage>1510</lpage><pub-id pub-id-type="doi">10.1185/030079904X2763</pub-id><pub-id pub-id-type="pmid">15383200</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ossareh</surname><given-names>S</given-names></name><name><surname>Roozbeh</surname><given-names>J</given-names></name><name><surname>Krishnan</surname><given-names>M</given-names></name><name><surname>Liakopoulos</surname><given-names>V</given-names></name><name><surname>Bargman</surname><given-names>JM</given-names></name><name><surname>Oreopoulos</surname><given-names>DG</given-names></name></person-group><article-title>Fatigue in chronic dialysis patients</article-title><source>Int Urol Nephrol</source><year>2003</year><volume>35</volume><fpage>535</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1023/B:UROL.0000025610.67447.b9</pub-id><pub-id pub-id-type="pmid">15198163</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a-L&#x000f3;pez</surname><given-names>E</given-names></name><name><surname>Carrero</surname><given-names>JJ</given-names></name><name><surname>Suliman</surname><given-names>ME</given-names></name><name><surname>Lindholm</surname><given-names>B</given-names></name><name><surname>Stenvinkel</surname><given-names>P</given-names></name></person-group><article-title>Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis</article-title><source>Perit Dial Int</source><year>2007</year><volume>27</volume><issue>Suppl 2</issue><fpage>S205</fpage><lpage>S209</lpage><pub-id pub-id-type="pmid">17556305</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fortes</surname><given-names>PC</given-names></name><name><surname>de Moraes</surname><given-names>TP</given-names></name><name><surname>Mendes</surname><given-names>JG</given-names></name><name><surname>Stinghen</surname><given-names>AE</given-names></name><name><surname>Ribeiro</surname><given-names>SC</given-names></name><name><surname>Pecoits-Filho</surname><given-names>R</given-names></name></person-group><article-title>Insulin resistance and glucose homeostasis in peritoneal dialysis</article-title><source>Perit Dial Int</source><year>2009</year><volume>29</volume><issue>Suppl 2</issue><fpage>S145</fpage><lpage>S148</lpage><pub-id pub-id-type="pmid">19270204</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Foley</surname><given-names>RN</given-names></name><name><surname>Collins</surname><given-names>AJ</given-names></name></person-group><article-title>Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States</article-title><source>Kidney Int</source><year>2004</year><volume>65</volume><fpage>1864</fpage><lpage>1869</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00584.x</pub-id><pub-id pub-id-type="pmid">15086928</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Pisoni</surname><given-names>RL</given-names></name><name><surname>Combe</surname><given-names>C</given-names></name><etal/></person-group><article-title>Anaemia in five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)</article-title><source>Nephrol Dial Transplant</source><year>2004</year><volume>19</volume><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfg458</pub-id><pub-id pub-id-type="pmid">14671047</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valderr&#x000e1;bano</surname><given-names>F</given-names></name></person-group><article-title>Quality of life benefits of early anaemia treatment</article-title><source>Nephrol Dial Transplant</source><year>2000</year><volume>15</volume><issue>Suppl 3</issue><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.ndt.a027972</pub-id><pub-id pub-id-type="pmid">11032354</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Covic</surname><given-names>A</given-names></name><name><surname>Eckardt</surname><given-names>KU</given-names></name><name><surname>Wiecek</surname><given-names>A</given-names></name><name><surname>Vanholder</surname><given-names>R</given-names></name><collab>ERA-EDTA ERBP Advisory Board</collab></person-group><article-title>Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP)</article-title><source>Nephrol Dial Transplant</source><year>2009</year><volume>24</volume><fpage>348</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfn653</pub-id><pub-id pub-id-type="pmid">19037082</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group</collab></person-group><article-title>KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease</article-title><source>Kidney Int Suppl</source><year>2012</year><volume>2</volume><fpage>279</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1038/kisup.2012.37</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macdougall</surname><given-names>IC</given-names></name><name><surname>Gray</surname><given-names>SJ</given-names></name><name><surname>Elston</surname><given-names>O</given-names></name><etal/></person-group><article-title>Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients</article-title><source>J Am Soc Nephrol</source><year>1999</year><volume>10</volume><fpage>2392</fpage><lpage>2395</lpage><pub-id pub-id-type="pmid">10541299</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halstenson</surname><given-names>CE</given-names></name><name><surname>Macres</surname><given-names>M</given-names></name><name><surname>Katz</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Comparative pharmacokinetics and pharmacodynamics of epoetin beta</article-title><source>Clin Pharmacol Ther</source><year>1991</year><volume>50</volume><fpage>702</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1038/clpt.1991.210</pub-id><pub-id pub-id-type="pmid">1752115</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Testing a single monthly dose of darbepoetin alpha to maintain hemoglobin levels in continuous ambulatory peritoneal dialysis patients</article-title><source>Adv Perit Dial</source><year>2011</year><volume>27</volume><fpage>60</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">22073831</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodoridis</surname><given-names>M</given-names></name><name><surname>Passadakis</surname><given-names>P</given-names></name><name><surname>Kriki</surname><given-names>P</given-names></name><etal/></person-group><article-title>Efficient monthly subcutaneous administration of darbepoetin in stable CAPD patients</article-title><source>Perit Dial Int</source><year>2005</year><volume>25</volume><fpage>564</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">16411523</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiramatsu</surname><given-names>M</given-names></name><name><surname>Kubota</surname><given-names>M</given-names></name><name><surname>Iwaksi</surname><given-names>M</given-names></name><name><surname>Panagoutsos</surname><given-names>S</given-names></name><name><surname>Yannatos</surname><given-names>E</given-names></name><name><surname>Kantartzi</surname><given-names>K</given-names></name><collab>KRN321 A09 Study Group</collab></person-group><article-title>Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients</article-title><source>Ther Apher Dial</source><year>2008</year><volume>12</volume><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1111/j.1744-9987.2007.00525.x</pub-id><pub-id pub-id-type="pmid">18257808</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macdougall</surname><given-names>IC</given-names></name><name><surname>Robson</surname><given-names>R</given-names></name><name><surname>Opatrna</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease</article-title><source>Clin J Am Soc Nephrol</source><year>2006</year><volume>1</volume><fpage>1211</fpage><lpage>1215</lpage><pub-id pub-id-type="doi">10.2215/CJN.00730306</pub-id><pub-id pub-id-type="pmid">17699350</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Villa</surname><given-names>G</given-names></name><name><surname>de Francisco</surname><given-names>ALM</given-names></name><collab>on behalf of the BA16286 Study Investigators</collab><etal/></person-group><article-title>Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration</article-title><source>Curr Med Res Opin</source><year>2007</year><volume>23</volume><fpage>969</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1185/030079907X182103</pub-id><pub-id pub-id-type="pmid">17519064</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>NW</given-names></name><name><surname>Fishbane</surname><given-names>S</given-names></name><name><surname>Ca&#x000f1;edo</surname><given-names>FV</given-names></name><collab>MAXIMA Study Investigators</collab><etal/></person-group><article-title>Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA)</article-title><source>Lancet</source><year>2007</year><volume>370</volume><fpage>1415</fpage><lpage>1421</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(07)61599-2</pub-id><pub-id pub-id-type="pmid">17950856</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulowicz</surname><given-names>W</given-names></name><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Ryckelynck</surname><given-names>JP</given-names></name><collab>PROTOS Study Investigators</collab><etal/></person-group><article-title>Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly</article-title><source>Clin J Am Soc Nephrol</source><year>2007</year><volume>2</volume><fpage>637</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.2215/CJN.03631006</pub-id><pub-id pub-id-type="pmid">17699476</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fliser</surname><given-names>D</given-names></name><name><surname>Kleophas</surname><given-names>W</given-names></name><name><surname>Dellanna</surname><given-names>F</given-names></name><etal/></person-group><article-title>Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study</article-title><source>Curr Med Res Opin</source><year>2010</year><volume>26</volume><fpage>1083</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1185/03007991003666652</pub-id><pub-id pub-id-type="pmid">20225992</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinreich</surname><given-names>T</given-names></name><name><surname>Leistikow</surname><given-names>F</given-names></name><name><surname>Hartmann</surname><given-names>HG</given-names></name><name><surname>Vollgraf</surname><given-names>G</given-names></name><name><surname>Dellanna</surname><given-names>F</given-names></name><collab>the SESAM Study Group</collab></person-group><article-title>Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients</article-title><source>Hemodial Int</source><year>2012</year><volume>16</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">22098689</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stegmayr</surname><given-names>BG</given-names></name></person-group><article-title>Better response to s.c. erythropoietin in CAPD than HD patients</article-title><source>Scand J Urol Nephrol</source><year>1997</year><volume>31</volume><fpage>183</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.3109/00365599709070327</pub-id><pub-id pub-id-type="pmid">9165584</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sieniawska</surname><given-names>M</given-names></name><name><surname>Roszkowska-Blaim</surname><given-names>M</given-names></name></person-group><article-title>Recombinant human erythropoietin dosage in children undergoing hemodialysis and continuous ambulatory peritoneal dialysis</article-title><source>Pediatr Nephrol</source><year>1997</year><volume>11</volume><fpage>628</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1007/s004670050352</pub-id><pub-id pub-id-type="pmid">9323294</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname><given-names>JJ</given-names></name><name><surname>Foley</surname><given-names>RN</given-names></name><name><surname>Gilbertson</surname><given-names>DT</given-names></name><name><surname>Vonesh</surname><given-names>EF</given-names></name><name><surname>Collins</surname><given-names>AJ</given-names></name></person-group><article-title>Hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis patients in the United States</article-title><source>J Am Soc Nephrol</source><year>2004</year><volume>15</volume><fpage>174</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1097/01.ASN.0000102475.94185.54</pub-id><pub-id pub-id-type="pmid">14694170</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coronel</surname><given-names>F</given-names></name><name><surname>Herrero</surname><given-names>JA</given-names></name><name><surname>Montenegro</surname><given-names>J</given-names></name><etal/></person-group><article-title>Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis</article-title><source>J Nephrol</source><year>2003</year><volume>16</volume><fpage>697</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">14733416</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>D</given-names></name><name><surname>Ford</surname><given-names>D</given-names></name><name><surname>Gilg</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name></person-group><article-title>UK Renal Registry 12th Annual Report (December 2009): chapter 9: anaemia variables in UK adult dialysis patients in 2008: national and centre-specific analyses</article-title><source>Nephrol Clin Pract</source><year>2010</year><volume>115</volume><issue>Suppl 1</issue><fpage>c153</fpage><lpage>c186</lpage><pub-id pub-id-type="doi">10.1159/000301164</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soffritti</surname><given-names>S</given-names></name><name><surname>Russo</surname><given-names>G</given-names></name><name><surname>Cantelli</surname><given-names>S</given-names></name><name><surname>Gilli</surname><given-names>G</given-names></name><name><surname>Catizone</surname><given-names>L</given-names></name></person-group><article-title>Maintaining over time clinical performance targets on anaemia correction in unselected population on chronic dialysis at 20 Italian centres. Data from a retrospective study for a clinical audit</article-title><source>BMC Nephrol</source><year>2009</year><volume>10</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/1471-2369-10-33</pub-id><pub-id pub-id-type="pmid">19852833</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>St Peter</surname><given-names>WL</given-names></name><name><surname>Obrador</surname><given-names>GT</given-names></name><name><surname>Roberts</surname><given-names>TL</given-names></name><name><surname>Collins</surname><given-names>AJ</given-names></name></person-group><article-title>Trends in intravenous iron use among dialysis patients in the United States (1994&#x02013;2002)</article-title><source>Am J Kidney Dis</source><year>2005</year><volume>46</volume><fpage>650</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2005.06.018</pub-id><pub-id pub-id-type="pmid">16183420</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Del Vecchio</surname><given-names>L</given-names></name><name><surname>Andrulli</surname><given-names>S</given-names></name></person-group><article-title>The modality of dialysis treatment: does it influence the response to erythropoietin treatment?</article-title><source>Nephrol Dial Transplant</source><year>2001</year><volume>16</volume><fpage>1971</fpage><lpage>1974</lpage><pub-id pub-id-type="doi">10.1093/ndt/16.10.1971</pub-id><pub-id pub-id-type="pmid">11572880</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>House</surname><given-names>AA</given-names></name><name><surname>Pham</surname><given-names>B</given-names></name><name><surname>Pag&#x000e9;</surname><given-names>DE</given-names></name></person-group><article-title>Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities</article-title><source>Nephrol Dial Transplant</source><year>1998</year><volume>13</volume><fpage>1763</fpage><lpage>1769</lpage><pub-id pub-id-type="doi">10.1093/ndt/13.7.1763</pub-id><pub-id pub-id-type="pmid">9681725</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Aljama</surname><given-names>P</given-names></name><name><surname>B&#x000e1;r&#x000e1;ny</surname><given-names>P</given-names></name><collab>European Best Practice Guidelines Working Group</collab><etal/></person-group><article-title>Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure</article-title><source>Nephrol Dial Transplant</source><year>2004</year><volume>19</volume><issue>Suppl 2</issue><fpage>ii1</fpage><lpage>ii47</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfh1032</pub-id><pub-id pub-id-type="pmid">15206425</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Greene</surname><given-names>T</given-names></name><etal/></person-group><article-title>Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values</article-title><source>Clin Chem</source><year>2007</year><volume>53</volume><fpage>766</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2006.077180</pub-id><pub-id pub-id-type="pmid">17332152</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fishbane</surname><given-names>S</given-names></name><name><surname>Berns</surname><given-names>JS</given-names></name></person-group><article-title>Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin</article-title><source>Kidney Int</source><year>2005</year><volume>68</volume><fpage>1337</fpage><lpage>1343</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2005.00532.x</pub-id><pub-id pub-id-type="pmid">16105069</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Putten</surname><given-names>K</given-names></name><name><surname>van der Baan</surname><given-names>FH</given-names></name><name><surname>Schellekens</surname><given-names>H</given-names></name><name><surname>Gaillard</surname><given-names>CA</given-names></name></person-group><article-title>Hemoglobin variability in patients with chronic kidney disease in the Netherlands</article-title><source>Int J Artif Organs</source><year>2009</year><volume>32</volume><fpage>787</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">20020410</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellanna</surname><given-names>F</given-names></name><name><surname>Winkler</surname><given-names>RE</given-names></name><name><surname>Bozkurt</surname><given-names>F</given-names></name><collab>MIRACEL Study Group</collab><etal/></person-group><article-title>Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study</article-title><source>Int J Clin Pract</source><year>2011</year><volume>65</volume><fpage>64</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1111/j.1742-1241.2010.02551.x</pub-id><pub-id pub-id-type="pmid">21091595</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>JF</given-names></name><name><surname>de Francisco</surname><given-names>A</given-names></name><name><surname>Nassar</surname><given-names>G</given-names></name><name><surname>Canaud</surname><given-names>B</given-names></name></person-group><article-title>Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease</article-title><source>Clin Nephrol</source><year>2011</year><volume>76</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.5414/CN106847</pub-id><pub-id pub-id-type="pmid">21722600</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selby</surname><given-names>NM</given-names></name><name><surname>Fonseca</surname><given-names>SA</given-names></name><name><surname>Fluck</surname><given-names>RJ</given-names></name><name><surname>Taal</surname><given-names>MW</given-names></name></person-group><article-title>Hemoglobin variability with epoetin beta and continuous erythropoiesis receptor activator in patients on peritoneal dialysis</article-title><source>Perit Dial Int</source><year>2012</year><volume>32</volume><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.3747/pdi.2010.00299</pub-id><pub-id pub-id-type="pmid">22045101</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roche</surname><given-names>A</given-names></name><name><surname>Macdougall</surname><given-names>IC</given-names></name><name><surname>Walker</surname><given-names>RG</given-names></name></person-group><article-title>Hemoglobin fluctuations in patients on haemodialysis treated with ESAs: clinical observations from two centres</article-title><source>Curr Med Res Opin</source><year>2009</year><volume>25</volume><fpage>2971</fpage><lpage>2976</lpage><pub-id pub-id-type="doi">10.1185/03007990903350029</pub-id><pub-id pub-id-type="pmid">19842997</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbertson</surname><given-names>DT</given-names></name><name><surname>Ebben</surname><given-names>JP</given-names></name><name><surname>Foley</surname><given-names>RN</given-names></name><name><surname>Weinhandl</surname><given-names>ED</given-names></name><name><surname>Bradbury</surname><given-names>BD</given-names></name><name><surname>Collins</surname><given-names>AJ</given-names></name></person-group><article-title>Hemoglobin level variability: associations with mortality</article-title><source>Clin J Am Soc Nephrol</source><year>2008</year><volume>3</volume><fpage>133</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.2215/CJN.01610407</pub-id><pub-id pub-id-type="pmid">18045862</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrera</surname><given-names>F</given-names></name><name><surname>Lok</surname><given-names>CE</given-names></name><name><surname>de Francisco</surname><given-names>A</given-names></name><etal/></person-group><article-title>Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial</article-title><source>Nephrol Dial Transplant</source><year>2010</year><volume>25</volume><fpage>4009</fpage><lpage>4017</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfq305</pub-id><pub-id pub-id-type="pmid">20522670</pub-id></element-citation></ref></ref-list></back></article>